KR20230047056A - 유방암 치료제 - Google Patents

유방암 치료제 Download PDF

Info

Publication number
KR20230047056A
KR20230047056A KR1020227045161A KR20227045161A KR20230047056A KR 20230047056 A KR20230047056 A KR 20230047056A KR 1020227045161 A KR1020227045161 A KR 1020227045161A KR 20227045161 A KR20227045161 A KR 20227045161A KR 20230047056 A KR20230047056 A KR 20230047056A
Authority
KR
South Korea
Prior art keywords
breast cancer
estrogen receptor
acceptable salt
pharmacologically acceptable
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227045161A
Other languages
English (en)
Korean (ko)
Inventor
사토시 가와노
사오리 미야노
교코 니시바타
사요 후쿠시마
Original Assignee
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에자이 알앤드디 매니지먼트 가부시키가이샤
Publication of KR20230047056A publication Critical patent/KR20230047056A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
KR1020227045161A 2020-07-31 2021-07-29 유방암 치료제 Pending KR20230047056A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JPJP-P-2020-130935 2020-07-31
JP2020130935 2020-07-31
JP2020163258 2020-09-29
JPJP-P-2020-163258 2020-09-29
PCT/JP2021/028008 WO2022025150A1 (ja) 2020-07-31 2021-07-29 乳がん治療剤

Publications (1)

Publication Number Publication Date
KR20230047056A true KR20230047056A (ko) 2023-04-06

Family

ID=80035757

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227045161A Pending KR20230047056A (ko) 2020-07-31 2021-07-29 유방암 치료제

Country Status (11)

Country Link
US (1) US20230172924A1 (https=)
EP (1) EP4151212A4 (https=)
JP (1) JP7792336B2 (https=)
KR (1) KR20230047056A (https=)
CN (1) CN115996722A (https=)
AU (1) AU2021315234A1 (https=)
BR (1) BR112022027069A2 (https=)
CA (1) CA3185174A1 (https=)
MX (1) MX2023000060A (https=)
TW (1) TW202220652A (https=)
WO (1) WO2022025150A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014235614A (ja) 2013-06-03 2014-12-15 株式会社ゼネット 総合学習支援ネットワークシステム及び総合学習支援方法
JP2017217935A (ja) 2016-06-03 2017-12-14 株式会社東海理化電機製作所 ステアリングスイッチ装置
KR20180015079A (ko) 2016-08-02 2018-02-12 다이요 유덴 가부시키가이샤 적층 세라믹 콘덴서
US20180303817A1 (en) 2015-12-17 2018-10-25 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
WO2019189241A1 (ja) 2018-03-28 2019-10-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2809312A1 (en) * 2012-01-31 2014-12-10 Novartis AG Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer
AR094812A1 (es) * 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
KR102344105B1 (ko) 2014-08-18 2021-12-29 에자이 알앤드디 매니지먼트 가부시키가이샤 모노시클릭 피리딘 유도체의 염 및 이의 결정
EP3275442B1 (en) 2015-03-25 2021-07-28 National Cancer Center Therapeutic agent for bile duct cancer
EP4122465A4 (en) * 2020-04-17 2024-03-20 Eisai R&D Management Co., Ltd. THERAPEUTIC AGENT AGAINST BREAST CANCER

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014235614A (ja) 2013-06-03 2014-12-15 株式会社ゼネット 総合学習支援ネットワークシステム及び総合学習支援方法
US20180303817A1 (en) 2015-12-17 2018-10-25 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
JP2017217935A (ja) 2016-06-03 2017-12-14 株式会社東海理化電機製作所 ステアリングスイッチ装置
KR20180015079A (ko) 2016-08-02 2018-02-12 다이요 유덴 가부시키가이샤 적층 세라믹 콘덴서
WO2019189241A1 (ja) 2018-03-28 2019-10-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
[비특허문헌 1] Howell et al.,"Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized Trial", Journal of Clinical Oncology, 2004, 22(9), 1605-1613.
[비특허문헌 2] Deeks et al.,"Exemestane A Review of its Use in Postmenopausal Women with Breast Cancer" Drugs, 2009, 69(7), 889-918

Also Published As

Publication number Publication date
TW202220652A (zh) 2022-06-01
JP7792336B2 (ja) 2025-12-25
US20230172924A1 (en) 2023-06-08
BR112022027069A2 (pt) 2023-02-07
JPWO2022025150A1 (https=) 2022-02-03
AU2021315234A1 (en) 2023-01-19
MX2023000060A (es) 2023-02-01
CA3185174A1 (en) 2022-02-03
EP4151212A1 (en) 2023-03-22
EP4151212A4 (en) 2024-04-10
WO2022025150A1 (ja) 2022-02-03
CN115996722A (zh) 2023-04-21

Similar Documents

Publication Publication Date Title
KR102318306B1 (ko) 암의 치료를 위한 조합 요법
CN106488767A (zh) 调节雌激素受体突变体的方法和组合物
CN106572990A (zh) 含有雌激素受体调节剂的治疗性组合产品
EP3581183A1 (en) Tumor-treating pharmaceutical composition
TW200843766A (en) Treatment of melanoma
CA3233554A1 (en) Combination therapy using a ptpn11 inhibitor and a kras g12c inhibitor
CN101222850B (zh) 治疗对药物有抗性的癌症的方法
US20230149381A1 (en) Breast cancer therapeutic agent
EP1845990B1 (en) Treatment of metastasized tumors
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
KR20230047056A (ko) 유방암 치료제
JP6748704B2 (ja) 抗癌治療剤
TW202342043A (zh) 使用ptpn11抑制劑及egfr抑制劑之組合療法
RU2847580C1 (ru) Терапевтическое средство против рака молочной железы
WO2016012982A1 (en) Combination therapy for the treatment of resistant breast cancer
US20090062246A1 (en) Therapeutic treatment-014
WO2025167971A1 (zh) Pkmyt1抑制剂的药物组合及其用途
EP4638443A1 (en) Transient receptor potential vanilloid 6 inhibitors
JP2023046235A (ja) 医薬組成物及びｓｔａｔ３のリン酸化阻害剤
WO2009138779A1 (en) Combination comprising 4- (3-chloro-2-fluoroanilino) -7-meth0xy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxyjquinazoline
TW201420102A (zh) 組合療法
CN101366716A (zh) 雷洛昔芬类化合物在制备防治良性前列腺增生症药物中的应用
CN101146538A (zh) 转移瘤的治疗
HK40007092A (en) Methods of treating prostate cancer
HK1230983A1 (en) Methods and compositions for modulating estrogen receptor mutants

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000